HRP20050655A2 - Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases - Google Patents
Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseasesInfo
- Publication number
- HRP20050655A2 HRP20050655A2 HR20050655A HRP20050655A HRP20050655A2 HR P20050655 A2 HRP20050655 A2 HR P20050655A2 HR 20050655 A HR20050655 A HR 20050655A HR P20050655 A HRP20050655 A HR P20050655A HR P20050655 A2 HRP20050655 A2 HR P20050655A2
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- prevention
- cardiopulmonary
- pulmonary
- cardiovascular
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 201000006306 Cor pulmonale Diseases 0.000 title abstract 2
- 208000019693 Lung disease Diseases 0.000 title abstract 2
- 230000002612 cardiopulmonary effect Effects 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 2
- 208000017169 kidney disease Diseases 0.000 title abstract 2
- 230000002685 pulmonary effect Effects 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title 1
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 abstract 4
- 230000002265 prevention Effects 0.000 abstract 3
- 239000005537 C09CA07 - Telmisartan Substances 0.000 abstract 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 2
- 208000001280 Prediabetic State Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229960005187 telmisartan Drugs 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008753 endothelial function Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000029865 regulation of blood pressure Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10301372A DE10301372A1 (de) | 2003-01-16 | 2003-01-16 | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
| DE10335027A DE10335027A1 (de) | 2003-07-31 | 2003-07-31 | Verwendung von Angiotensin II Rezeptor Antagonisten |
| PCT/EP2004/000175 WO2004062729A1 (de) | 2003-01-16 | 2004-01-14 | Pharmazeutische kombination zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20050655A2 true HRP20050655A2 (en) | 2006-05-31 |
Family
ID=32714792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050655A HRP20050655A2 (en) | 2003-01-16 | 2005-07-15 | Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20050004193A1 (da) |
| EP (2) | EP1587584B1 (da) |
| JP (1) | JP2006515877A (da) |
| KR (1) | KR20050092119A (da) |
| AT (1) | ATE362782T1 (da) |
| AU (1) | AU2004204353A1 (da) |
| BR (1) | BRPI0406812A (da) |
| CA (1) | CA2513281C (da) |
| CY (1) | CY1106775T1 (da) |
| DE (1) | DE502004003880D1 (da) |
| DK (1) | DK1587584T3 (da) |
| EA (1) | EA009886B1 (da) |
| EC (1) | ECSP055914A (da) |
| ES (1) | ES2287689T3 (da) |
| HR (1) | HRP20050655A2 (da) |
| MX (1) | MXPA05007559A (da) |
| NO (1) | NO20053793L (da) |
| PL (1) | PL376213A1 (da) |
| PT (1) | PT1587584E (da) |
| RS (1) | RS20050536A (da) |
| SI (1) | SI1587584T1 (da) |
| WO (1) | WO2004062729A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
| JP5134963B2 (ja) * | 2004-11-05 | 2013-01-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | テルミサルタンとアムロジピンを含む二層錠剤 |
| WO2007051007A2 (en) * | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
| US20090030057A1 (en) * | 2005-11-22 | 2009-01-29 | Shlomit Wizel | Pharmaceutical composition of telmisartan |
| DK2089047T3 (da) * | 2006-12-11 | 2013-02-18 | 3D Matrix Inc | Sammensætninger og fremgangsmåder til beskyttelse og regenerering af hjerte-væv |
| US20110117194A1 (en) | 2008-04-29 | 2011-05-19 | Hanall Biopharma Co., Ltd. | Pharmaceutical formulation containing angiotensin-ii receptor blocker |
| WO2010075347A2 (en) * | 2008-12-23 | 2010-07-01 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone |
| WO2013083286A1 (en) * | 2011-12-09 | 2013-06-13 | Farmicom Pharmaceutical Company D.O.O. | TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR |
| WO2013136277A1 (en) * | 2012-03-13 | 2013-09-19 | Unimark Remedies Ltd. | Pharmaceutical compositions for treatment of cardiovascular diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK283348B6 (sk) * | 1996-04-05 | 2003-06-03 | Takeda Chemical Industries, Ltd. | Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II |
| US20010006656A1 (en) * | 1999-02-17 | 2001-07-05 | University Of Washington | Methods and compositions for inhibiting inflammation associated with pulmonary disease |
| WO2001015674A2 (en) * | 1999-08-30 | 2001-03-08 | Aventis Pharma Deutschland Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| EP1326604A2 (en) * | 2000-04-12 | 2003-07-16 | Novartis AG | Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups |
| US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| CA2420844A1 (en) * | 2000-08-30 | 2003-02-28 | Sankyo Company, Limited | Medicinal compositions for preventing or treating heart failure |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| JP4585198B2 (ja) * | 2002-12-27 | 2010-11-24 | 武田薬品工業株式会社 | 体重増加抑制剤 |
-
2004
- 2004-01-14 AU AU2004204353A patent/AU2004204353A1/en not_active Abandoned
- 2004-01-14 PL PL04376213A patent/PL376213A1/xx not_active Application Discontinuation
- 2004-01-14 AT AT04701918T patent/ATE362782T1/de active
- 2004-01-14 SI SI200430377T patent/SI1587584T1/sl unknown
- 2004-01-14 US US10/757,015 patent/US20050004193A1/en not_active Abandoned
- 2004-01-14 DK DK04701918T patent/DK1587584T3/da active
- 2004-01-14 BR BR0406812-2A patent/BRPI0406812A/pt not_active IP Right Cessation
- 2004-01-14 PT PT04701918T patent/PT1587584E/pt unknown
- 2004-01-14 EP EP04701918A patent/EP1587584B1/de not_active Expired - Lifetime
- 2004-01-14 MX MXPA05007559A patent/MXPA05007559A/es active IP Right Grant
- 2004-01-14 CA CA2513281A patent/CA2513281C/en not_active Expired - Fee Related
- 2004-01-14 EP EP07105299A patent/EP1818056A1/de not_active Withdrawn
- 2004-01-14 WO PCT/EP2004/000175 patent/WO2004062729A1/de active IP Right Grant
- 2004-01-14 KR KR1020057013209A patent/KR20050092119A/ko not_active Application Discontinuation
- 2004-01-14 EA EA200501057A patent/EA009886B1/ru not_active IP Right Cessation
- 2004-01-14 ES ES04701918T patent/ES2287689T3/es not_active Expired - Lifetime
- 2004-01-14 RS YUP-2005/0536A patent/RS20050536A/sr unknown
- 2004-01-14 JP JP2006500558A patent/JP2006515877A/ja active Pending
- 2004-01-14 DE DE502004003880T patent/DE502004003880D1/de not_active Expired - Lifetime
-
2005
- 2005-07-12 EC EC2005005914A patent/ECSP055914A/es unknown
- 2005-07-15 HR HR20050655A patent/HRP20050655A2/xx not_active Application Discontinuation
- 2005-08-10 NO NO20053793A patent/NO20053793L/no not_active Application Discontinuation
-
2007
- 2007-07-30 CY CY20071101012T patent/CY1106775T1/el unknown
-
2011
- 2011-04-13 US US13/086,131 patent/US20110190277A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0406812A (pt) | 2005-12-27 |
| PT1587584E (pt) | 2007-06-11 |
| AU2004204353A1 (en) | 2004-07-29 |
| US20110190277A1 (en) | 2011-08-04 |
| WO2004062729A1 (de) | 2004-07-29 |
| PL376213A1 (en) | 2005-12-27 |
| SI1587584T1 (sl) | 2007-10-31 |
| DK1587584T3 (da) | 2007-09-24 |
| ECSP055914A (es) | 2006-03-01 |
| US20050004193A1 (en) | 2005-01-06 |
| JP2006515877A (ja) | 2006-06-08 |
| DE502004003880D1 (de) | 2007-07-05 |
| EP1818056A1 (de) | 2007-08-15 |
| EP1587584A1 (de) | 2005-10-26 |
| MXPA05007559A (es) | 2005-09-21 |
| CY1106775T1 (el) | 2012-05-23 |
| NO20053793L (no) | 2005-08-10 |
| WO2004062729A8 (de) | 2004-10-07 |
| EA200501057A1 (ru) | 2006-02-24 |
| RS20050536A (en) | 2007-09-21 |
| EP1587584B1 (de) | 2007-05-23 |
| KR20050092119A (ko) | 2005-09-20 |
| ATE362782T1 (de) | 2007-06-15 |
| ES2287689T3 (es) | 2007-12-16 |
| EA009886B1 (ru) | 2008-04-28 |
| CA2513281A1 (en) | 2004-07-29 |
| CA2513281C (en) | 2012-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20050655A2 (en) | Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases | |
| RS20050537A (en) | Pharmaceutical combination of telmisartan and atorvastatin for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases | |
| Toussaint et al. | The evaluation and management of thermal injuries: 2014 update | |
| Albillos et al. | Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension | |
| HRP20200828T1 (hr) | Farmaceutski pripravak koji sadrži sglt2-inhibitor, dpp-iv-inhibitor i prema potrebi jedno dodatno antidijabetičko sredstvo, te njegove uporabe | |
| WO2001058472A3 (en) | Botulinum toxin pharmaceutical compositions | |
| Thomas et al. | Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease | |
| Huang et al. | Acute lung injury in patients with severe acute pancreatitis | |
| Fulenwider et al. | LeVeen vs denver peritoneovenous shunts for intractable ascites of cirrhosis: a randomized, prospective trial | |
| JPWO2006011397A1 (ja) | 糖尿病の予防または治療のための薬剤 | |
| Appel | Detecting and controlling diabetic nephropathy: what do we know | |
| HK1058190A1 (en) | Novel heterocyclic analogs of diphenylethylene compounds | |
| Hayes et al. | Ethanol causes epicardial coronary artery vasoconstriction in the intact dog. | |
| Schwaber et al. | Hazard of sauna use after strenuous exercise | |
| Pennypacker et al. | Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole | |
| Larsson et al. | Left ventricular function before and after kidney transplantation. A prospective study in patients with juvenile-onset diabetes mellitus | |
| Hauken | Fixed drug eruption and pseudoephedrine | |
| RU2006123831A (ru) | Способ предоперационной диагностики и профилактики гемокоагуляционных осложнений | |
| KR20090096640A (ko) | 당뇨병성 뉴로퍼시 치료제 | |
| Buzio et al. | Renal effects of nifedipine and captopril in patients with essential hypertension and reduced renal reserve. | |
| JPWO2005112944A1 (ja) | 糖尿病の予防または治療のための薬剤 | |
| Sanderson | Heart failure-a growing epidemic in Asia | |
| Alhamdani | Possible beneficial effects of amlodipine, lisinopril, and their combination on lipid profile in hypertensive patients | |
| Salomon et al. | Special problems in treating tuberculosis | |
| Feldman et al. | Nocturnal home oximetry in detecting the sleep apnea-hypopnea syndrome and in working up hypersomnolence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20071231 Year of fee payment: 5 |
|
| OBST | Application withdrawn |